Search

Findings Could Inform the Development of a Blood Test for Early Cancer Detection

… Saturday, June 3, 2017 Findings from an early study evaluating a sophisticated new genomic-sequencing approach that analyzes cell-free DNA (cfDNA) in the blood of people with advanced cancer will help inform development of a future assay that could potentially detect cancer in its earliest stages, according

Most children face pressures growing up — including from their parents and peers. Vik Gill wrestled with circumstances “that may sound more familiar to any child of first-generation immigrants.

… Friday, May 6, 2022 Most children face pressures growing up — including from their parents and peers. Vik Gill wrestled with circumstances “that may sound more familiar to any child of first-generation immigrants,” he says “I was raised in a pretty culturally Indian household,” says Vik, an analyst for

A multicenter team led by Memorial Sloan Kettering neurologist and researcher Ingo K. Mellinghoff has uncovered the relationship between two proteins that play a critical role in glioblastoma, the most common form of brain cancer.

… Thursday, July 1, 2010 Summary A multicenter team led by Memorial Sloan Kettering neurologist and researcher Ingo K. Mellinghoff has uncovered the relationship between two proteins that play a critical role in glioblastoma, the most common form of brain cancer. A multicenter team led by Memorial Sloan

Hartford Healthcare system in Connecticut has been selected as the first MSK Cancer Alliance member, established to enhance delivery of care, improve patient outcomes, and advance research.

… Tuesday, September 17, 2013 Summary Hartford Healthcare system in Connecticut has been selected as the first MSK Cancer Alliance member, established to enhance delivery of care, improve patient outcomes, and advance research. Memorial Sloan Kettering today launched a transformative initiative to improve

Scott Stuart, Chair of the Boards of Trustees and Governing Trustees at Memorial Sloan Kettering Cancer Center (MSK), has been recognized as a Notable Nonprofit Board Leader in the 2023 Crain’s New York Business special editorial feature.

… Tuesday, October 10, 2023 Scott Stuart, Chair of the Boards of Trustees and Governing Trustees at Memorial Sloan Kettering Cancer Center (MSK), has been recognized as a Notable Nonprofit Board Leader in the 2023 Crain’s New York Business special editorial feature. This list honors exceptional nonprofit

Dr. Mara Sherman's lab at the Sloan Kettering Institute is “all pancreas, all the time.” Learn how her research program is illuminating interactions between cancer cells and the dense weave of fibrous cells that surrounds and protects pancreatic tumors.

… Monday, June 24, 2024 While the overall five-year survival rate for pancreatic cancer is slowly improving, it remains discouragingly low — just 13%, according to the American Cancer Society . And the odds are even worse if the cancer is discovered after it has spread to other organs. Dr. Mara Sherman

IBM, WellPoint, Inc., and Memorial Sloan Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to patients through individualized, evidence-based medicine.

… Friday, February 8, 2013 IBM (NYSE: IBM ), WellPoint, Inc. (NYSE: WLP ), and Memorial Sloan Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to

As 2017 draws to a close, take a look back at the scientific discoveries that deepened our understanding of cancer in the past year.

… Tuesday, December 5, 2017 This past year, Memorial Sloan Kettering researchers made important advances in basic and translational science that furthered our understanding of cancer and of how best to treat it. Here, we describe some of the year’s highlights. First CAR T Cell Therapies FDA Approved By

Scheduled to start in Summer 2025, this cohort program will facilitate tailored mentorship with MSK faculty, while providing insight into MSK's drug development resources and a pathway for future collaboration via the Accelerator.

… Wednesday, April 30, 2025 MSK recently announced the launch of a new cohort program in the MSK Therapeutics Accelerator . Scheduled to start in Summer 2025, this cohort program will facilitate tailored mentorship with MSK faculty, while providing insight into MSK’s drug development resources and a pathway

Research points to the role of a protein called MYB, which has long been known to play a role in cancer.

… Friday, February 5, 2021 Summary Research shows how a protein called MYB can be targeted, suggesting a new approach for drugs that could treat a range of cancers, especially myeloid leukemias in both children and adults. Disruption in the way genes turn on and off can cause tumors to grow and proliferate